Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice

References

• Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labelling claims. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed April 27, 2023.
   Google Scholar
• Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30(34):4249–4255. doi:10.1200/JCO.2012.42.5967
   PubMed Web of Science ®Google Scholar
• Rivera SC, Kyte DG, Aiyegbusi OL, et al. The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis. Health Qual Life Outcomes. 2019;17(1):156. doi:10.1186/s12955-019-1220-z
   PubMed Web of Science ®Google Scholar
• Ishaque S, Karnon J, Chen G, et al. A systematic review of randomised controlled trials evaluating the use of patient-reported outcome measures (PROMs). Qual Life Res. 2019;28(3):567–592. doi:10.1007/s11136-018-2016-z
   PubMed Web of Science ®Google Scholar
• Au H-J, Ringash J, Brundage M, et al. Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. Expert Rev Pharmacoecon Outcomes Res. 2010;10(2):119–128. doi:10.1586/erp.10.15
   PubMed Web of Science ®Google Scholar
• Gotay CC, Kawamoto CT, Bottomley A, et al. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol. 2008;26(8):1355–1363. doi:10.1200/JCO.2007.13.3439
   PubMed Web of Science ®Google Scholar
• Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes. 2009;7:102. doi:10.1186/1477-7525-7-102
   PubMed Web of Science ®Google Scholar
• Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10(9):865–871. doi:10.1016/S1470-2045(09)70200-1
   PubMed Web of Science ®Google Scholar
• Quinten C, Martinelli F, Coens C, et al. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer. 2014;120(2):302–311. doi:10.1002/cncr.28382
   PubMed Web of Science ®Google Scholar
• Grande GE, Farquhar MC, Barclay SIG, et al. Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients. Palliat Support Care. 2009;7(3):289–297. doi:10.1017/S1478951509990216
   PubMedGoogle Scholar
• Campbell R, Ju A, King MT, et al. Perceived benefits and limitations of using patient-reported outcome measures in clinical practice with individual patients: a systematic review of qualitative studies. Qual Life Res. 2022;31(6):1597–1620. doi:10.1007/s11136-021-03003-z
   PubMed Web of Science ®Google Scholar
• Petersen MA, Larsen H, Pedersen L, et al. Assessing health-related quality of life in palliative care: comparing patient and physician assessments. Eur J Cancer. 2006;42(8):1159–1166. doi:10.1016/j.ejca.2006.01.032
   PubMed Web of Science ®Google Scholar
• Roncolato FT, Joly F, O’Connell R, et al. Reducing uncertainty: predictors of stopping chemotherapy early and shortened survival time in platinum resistant/refractory ovarian cancer-the GCIG symptom benefit study. Oncologist. 2017;22(9):1117–1124. doi:10.1634/theoncologist.2017-0047
   PubMed Web of Science ®Google Scholar
• Roncolato FT, O’Connell RL, Joly F, et al. Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(>/=3) chemotherapy - The GCIG symptom benefit study (SBS). Gynecol Oncol. 2020;156(1):45–53. doi:10.1016/j.ygyno.2019.10.001
   PubMed Web of Science ®Google Scholar
• Armbrust R, Richter R, Woopen H, et al. Impact of health-related quality of life (HRQoL) on short-term mortality in patients with recurrent ovarian, fallopian or peritoneal carcinoma (the NOGGO-AGO QoL Prognosis-Score-Study): results of a meta-analysis in 2209 patients. ESMO Open. 2021;6(2):100081. doi:10.1016/j.esmoop.2021.100081
   PubMed Web of Science ®Google Scholar
• Kluetz PG, O’Connor DJ, Soltys K. Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada. Lancet Oncol. 2018;19(5):e267–e274. doi:10.1016/S1470-2045(18)30097-4
   PubMed Web of Science ®Google Scholar
• Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2017;28(11):2901–2905. doi:10.1093/annonc/mdw258
   PubMed Web of Science ®Google Scholar
• Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34(24):2925–2934. doi:10.1200/JCO.2016.68.2518
   PubMed Web of Science ®Google Scholar
• du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16(Suppl 8):viii7–viii12. doi:10.1093/annonc/mdi961
   PubMed Web of Science ®Google Scholar
• Joly F, Hilpert F, Okamoto A, et al. Fifth ovarian cancer consensus conference of the gynecologic cancer InterGroup: recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer. Eur J Cancer. 2017;78:133–138. doi:10.1016/j.ejca.2017.03.019
   PubMed Web of Science ®Google Scholar
• Quinten C, Maringwa J, Gotay CC, et al. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst. 2011;103(24):1851–1858. doi:10.1093/jnci/djr485
   PubMedGoogle Scholar
• Greimel E, Bottomley A, Cull A, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer. 2003;39(10):1402–1408. doi:10.1016/S0959-8049(03)00307-1
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Alvarez Secord A, Ehrisman JA, et al. Patient preferences in advanced or recurrent ovarian cancer. Cancer. 2014;120(23):3651–3659. doi:10.1002/cncr.28940
   PubMed Web of Science ®Google Scholar
• Kurtz JE, Gebski V, Sukhin V, et al. Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: a position paper from the GCIG symptom benefit committee. Gynecol Oncol. 2021;161(2):502–507. doi:10.1016/j.ygyno.2021.02.018
   PubMed Web of Science ®Google Scholar
• Friedlander M, Mercieca-Bebber RL, King MT. Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned. Ann Oncol. 2016;27(Suppl 1):i66–i71. doi:10.1093/annonc/mdw080
   PubMedGoogle Scholar
• Mercieca-Bebber R, Friedlander M, Kok P-S, et al. The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. Qual Life Res. 2016;25(10):2457–2465. doi:10.1007/s11136-016-1339-x
   PubMed Web of Science ®Google Scholar
• Mercieca-Bebber R, Friedlander M, Calvert M, et al. A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice. J Patient Rep Outcomes. 2017;1(1):5. doi:10.1186/s41687-017-0008-3
   PubMedGoogle Scholar
• Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34(6):557–565. doi:10.1200/JCO.2015.63.0830
   PubMed Web of Science ®Google Scholar
• Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318(2):197–198. doi:10.1001/jama.2017.7156
   PubMed Web of Science ®Google Scholar
• Denis F, Lethrosne C, Pourel N, et al. Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. J Natl Cancer Inst. 2017;109(9). doi:10.1093/jnci/djx029.
   PubMedGoogle Scholar
• Nipp R, Temel J. The patient knows best: incorporating patient-reported outcomes into routine clinical care. J Natl Cancer Inst. 2017;109(9). doi:10.1093/jnci/djx044
   PubMedGoogle Scholar
• Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014;32(14):1480–1501. doi:10.1200/JCO.2013.53.5948
   PubMed Web of Science ®Google Scholar
• Chen J, Ou L, Hollis SJ. A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res. 2013;13:211. doi:10.1186/1472-6963-13-211
   PubMed Web of Science ®Google Scholar
• VandenBos GR. APA Dictionary of Psychology. Second ed. Washington, DC: American Psychological Association; 2015.
   Google Scholar
• Schmier JK, Halpern MT. Patient recall and recall bias of health state and health status. Expert Rev Pharmacoecon Outcomes Res. 2004;4(2):159–163. doi:10.1586/14737167.4.2.159
   PubMedGoogle Scholar
• King MT, Dueck AC, Revicki DA. Can methods developed for interpreting group-level patient-reported outcome data be applied to individual patient management? Med Care. 2019;57(Suppl5 1):S38–s45. doi:10.1097/MLR.0000000000001111
   PubMedGoogle Scholar
• Nguyen H, Butow P, Dhillon H, et al. A review of the barriers to using Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs) in routine cancer care. J Med Radiat Sci. 2021;68(2):186–195. doi:10.1002/jmrs.421
   PubMed Web of Science ®Google Scholar
• Reeve BB, Wyrwich KW, Wu AW, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res. 2013;22(8):1889–1905. doi:10.1007/s11136-012-0344-y
   PubMed Web of Science ®Google Scholar
• Bhat G, Karakasis K, Oza AM. Measuring quality of life in ovarian cancer clinical trials-can we improve objectivity and cross trial comparisons? Cancers. 2020;12(11):3296. doi:10.3390/cancers12113296
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer. 1993;85(5):365–376. doi:10.1093/jnci/85.5.365
   PubMed Web of Science ®Google Scholar
• Cella D, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–579. doi:10.1200/JCO.1993.11.3.570
   PubMed Web of Science ®Google Scholar
• Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol. 2001;19(6):1809–1817. doi:10.1200/JCO.2001.19.6.1809
   PubMed Web of Science ®Google Scholar
• Cella D, Paul D, Yount S, et al. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest. 2003;21(4):526–535. doi:10.1081/CNV-120022366
   PubMed Web of Science ®Google Scholar
• Beaumont J, Yount S, Lalla D, et al. Validation of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Symptom Index (FOSI) in a Phase II clinical trial of pertuzumab in patients with advanced ovarian cancer. J Clin Oncol. 2007;25(18_suppl):16021. doi:10.1200/jco.2007.25.18_suppl.16021
   Web of Science ®Google Scholar
• King MT, Stockler MR, O’Connell RL, et al. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Qual Life Res. 2018;27(1):59–74. doi:10.1007/s11136-017-1729-8
   PubMed Web of Science ®Google Scholar
• Campbell R, King MT, Ross TL, et al. Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): an instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment. Gynecol Oncol. 2021;163(2):398–407. doi:10.1016/j.ygyno.2021.08.022
   PubMed Web of Science ®Google Scholar
• Campbell R, Costa DSJ, Stockler MR, et al. Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer. Gynecol Oncol. 2022;166(2):254–262. doi:10.1016/j.ygyno.2022.05.024
   PubMed Web of Science ®Google Scholar
• Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244–dju244. doi:10.1093/jnci/dju244
   PubMedGoogle Scholar
• Calvert M, King M, Mercieca-Bebber R, et al. SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. BMJ Open. 2021;11(6):e045105. doi:10.1136/bmjopen-2020-045105
   PubMed Web of Science ®Google Scholar
• Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA. 2018;319(5):483–494. doi:10.1001/jama.2017.21903
   PubMed Web of Science ®Google Scholar
• Chan EKH, Edwards TC, Haywood K, et al. Implementing patient-reported outcome measures in clinical practice: a companion guide to the ISOQOL user’s guide. Qual Life Res. 2019;28(3):621–627. doi:10.1007/s11136-018-2048-4
   PubMed Web of Science ®Google Scholar
• Goff B. Symptoms associated with ovarian cancer. Clin Obstet Gynecol. 2012;55(1):36–42. doi:10.1097/GRF.0b013e3182480523
   PubMed Web of Science ®Google Scholar
• Power J, Brown L, Ritvo P. A qualitative study examining psychosocial distress, coping, and social support across the stages and phases of epithelial ovarian cancer. Health Care Women Int. 2008;29(4):366–383. doi:10.1080/07399330701876521
   PubMed Web of Science ®Google Scholar
• Chase DM, Wenzel L. Health-related quality of life in ovarian cancer patients and its impact on clinical management. Expert Rev Pharmacoecon Outcomes Res. 2011;11(4):421–431. doi:10.1586/erp.11.41
   PubMed Web of Science ®Google Scholar
• Beesley VL, Ross TL, King MT, et al. Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns). Gynecol Oncol. 2022;164(2):437–445. doi:10.1016/j.ygyno.2021.12.006
   PubMed Web of Science ®Google Scholar
• Domenici L, Palaia I, Giorgini M, et al. Sexual health and quality of life assessment among ovarian cancer patients during chemotherapy. Oncology. 2016;91(4):205–210. doi:10.1159/000447403
   PubMedGoogle Scholar
• Beesley VL, Webber K, Nagle CM, et al. When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. Gynecol Oncol. 2020;159(1):179–186. doi:10.1016/j.ygyno.2020.07.029
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–2428. doi:10.1056/NEJMoa1911361
   PubMed Web of Science ®Google Scholar
• González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–2402. doi:10.1056/NEJMoa1910962
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505. doi:10.1056/NEJMoa1810858
   PubMed Web of Science ®Google Scholar
• Colombo N, Moore K, Scambia G, et al. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol Oncol. 2021;163(1):41–49. doi:10.1016/j.ygyno.2021.07.016
   PubMed Web of Science ®Google Scholar
• Moss HA, Chen L, Hershman DL, et al. Adherence to PARP inhibitor therapy among women with ovarian cancer. Gynecol Oncol. 2021;163(2):262–268. doi:10.1016/j.ygyno.2021.08.025
   PubMed Web of Science ®Google Scholar
• Gelber RD, Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol. 1986;4(12):1772–1779. doi:10.1200/JCO.1986.4.12.1772
   PubMed Web of Science ®Google Scholar
• Gelber RD, Goldhirsch A, Cavalli F. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med. 1991;114(8):621–628. doi:10.7326/0003-4819-114-8-621
   PubMed Web of Science ®Google Scholar
• Friedlander M, Gebski V, Gibbs E, et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, Phase 3 randomised trial. Lancet Oncol. 2018;19(8):1126–1134. doi:10.1016/S1470-2045(18)30343-7
   PubMed Web of Science ®Google Scholar
• Oza AM, Lorusso D, Aghajanian C, et al. Patient-centered outcomes in ARIEL3, a Phase III, randomized, placebo-controlled trial of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma. J Clin Oncol. 2020;38(30):3494–3505. doi:10.1200/JCO.19.03107
   PubMed Web of Science ®Google Scholar
• Chase DM, Marín MR, Backes F, et al. Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial. Gynecol Oncol. 2022;166(3):494–502. doi:10.1016/j.ygyno.2022.06.028
   PubMed Web of Science ®Google Scholar
• Joly F, Chabaud S, Cropet C, et al. Time without symptoms or toxicity (TWiST) in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib or placebo plus bevacizumab: analysis of PAOLA-1/ENGOT-ov25 phase III trial. J Clin Oncol. 2022;40(16_suppl):5562. doi:10.1200/JCO.2022.40.16_suppl.5562
   Web of Science ®Google Scholar
• Friedlander M, Moore KN, Colombo N, et al. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncol. 2021;22(5):632–642. doi:10.1016/S1470-2045(21)00098-X
   PubMed Web of Science ®Google Scholar
• Cancer Australia. Follow up of women with epithelial ovarian cancer: a clinical practice guideline developed by Cancer Australia. 2012.
   Google Scholar
• Cohen PA, Webb PM, King M, et al. Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer. Int J Gynecol Cancer. 2021;30:245.
   Google Scholar
• Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161–92. doi:10.1016/S0020-7292(06)60033-7
   PubMed Web of Science ®Google Scholar
• Lee YC, King MT, O’Connell RL, et al. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study. Int J Gynecol Cancer. 2022;32:761–768. doi:10.1136/ijgc-2021-003142
   PubMed Web of Science ®Google Scholar
• Friedlander ML, Stockler M, O’Connell R, et al. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. Int J Gynecol Cancer. 2014;24(5):857–864. doi:10.1097/IGC.0000000000000147
   PubMed Web of Science ®Google Scholar
• Hay CM, Courtney-Brooks M, Lefkowits C, et al. Symptom management in women with recurrent ovarian cancer: do patients and clinicians agree on what symptoms are most important? Gynecol Oncol. 2016;143(2):367–370. doi:10.1016/j.ygyno.2016.08.235
   PubMed Web of Science ®Google Scholar
• Chandwani KD, Zhao F, Morrow GR, et al. Lack of patient-clinician concordance in cancer patients: its relation with patient variables. J Pain Symptom Manage. 2017;53(6):988–998. doi:10.1016/j.jpainsymman.2016.12.347
   PubMed Web of Science ®Google Scholar
• Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32(13):1309–1316. doi:10.1200/JCO.2013.51.4240
   PubMed Web of Science ®Google Scholar
• Friedlander M, Stockler MR, O’Connell R, et al. Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥ 3 lines of chemotherapy (PPS ≥ 3)—the Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS). J Clin Oncol. 2015;33(15_suppl):5536.
   Web of Science ®Google Scholar
• Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004;22(17):3485–3490. doi:10.1200/JCO.2004.03.025
   PubMed Web of Science ®Google Scholar
• Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101(23):1624–1632. doi:10.1093/jnci/djp386
   PubMedGoogle Scholar
• Gilbert A, Sebag-Montefiore D, Davidson S, et al. Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic. Gynecol Oncol. 2015;136(3):429–439. doi:10.1016/j.ygyno.2014.11.071
   PubMed Web of Science ®Google Scholar
• Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22(4):714–724. doi:10.1200/JCO.2004.06.078
   PubMed Web of Science ®Google Scholar
• Donovan HS, Sereika SM, Wenzel LB, et al. Effects of the WRITE symptoms interventions on symptoms and quality of life among patients with recurrent ovarian cancers: an NRG oncology/GOG study (GOG-0259). J Clin Oncol. 2022;40(13):1464–1473. doi:10.1200/JCO.21.00656
   PubMed Web of Science ®Google Scholar
• Hanker LC, Loibl S, Burchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605–2612. doi:10.1093/annonc/mds203
   PubMed Web of Science ®Google Scholar
• Smith H, Smith TJ. The role of chemotherapy at the end of life: “when is enough, enough?”. JAMA. 2008;299(22):2667–2678. doi:10.1001/jama.299.22.2667
   PubMed Web of Science ®Google Scholar
• Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715–1724. doi:10.1200/JCO.2012.42.8375
   PubMed Web of Science ®Google Scholar
• von Gruenigen V, Daly B, Gibbons H, et al. Indicators of survival duration in ovarian cancer and implications for aggressiveness of care. Cancer. 2008;112(10):2221–2227. doi:10.1002/cncr.23391
   PubMed Web of Science ®Google Scholar
• Nevadunsky NS, Spoozak L, Gordon S, et al. End-of-life care of women with gynecologic malignancies: a pilot study. Int J Gynecol Cancer. 2013;23(3):546–552. doi:10.1097/IGC.0b013e3182842efa
   PubMed Web of Science ®Google Scholar
• Rochigneux P, Raoul JL, Beaussant Y, et al. Use of chemotherapy near the end of life: what factors matter? Ann Oncol. 2017;28(4):809–817. doi:10.1093/annonc/mdw654
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. End of life care. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/end-of-life-care. Accessed April 27, 2023.
   Google Scholar
• Palliation in gyne-oncology: patient expectations and assessment of care. Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382163. Accessed April 27, 2023.
   Google Scholar
• Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–207. doi:10.7326/0003-4819-158-3-201302050-00583
   PubMed Web of Science ®Google Scholar
• Chan A-W, Tetzlaff JM, Gotzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi:10.1136/bmj.e7586
   PubMed Web of Science ®Google Scholar
• Mercieca-Bebber R, Calvert M, Kyte D, et al. The administration of patient-reported outcome questionnaires in cancer trials: interviews with trial coordinators regarding their roles, experiences, challenges and training. Contemp Clin Trials Commun. 2018;9:23–32. doi:10.1016/j.conctc.2017.11.009
   PubMed Web of Science ®Google Scholar
• Kyte D, Ives J, Draper H, et al. Inconsistencies in quality of life data collection in clinical trials: a potential source of bias? Interviews with research nurses and trialists. PLoS One. 2013;8(10):e76625. doi:10.1371/journal.pone.0076625
   PubMed Web of Science ®Google Scholar
• Young T, De Haes H, Curran D, et al. Guidelines for assessing quality of life in EORTC clinical trials. 1999.
   Google Scholar
• QOL Office. Checklist of instructions for the administration of patient reported outcome measures; 2015. Available from: http://www.pocog.org.au/docview.aspx?id=355. Accessed March 27, 2023.
   Google Scholar
• Coens C, Pe M, Dueck AC, et al. International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL consortium. Lancet Oncol. 2020;21(2):e83–e96. doi:10.1016/S1470-2045(19)30790-9
   PubMed Web of Science ®Google Scholar
• Bottomley A, Pe M, Sloan J, et al. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol. 2016;17(11):e510–e514. doi:10.1016/S1470-2045(16)30510-1
   PubMed Web of Science ®Google Scholar
• Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814–822. doi:10.1001/jama.2013.879
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8(1):18. doi:10.1186/1741-7015-8-18
   PubMed Web of Science ®Google Scholar
• Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869. doi:10.1136/bmj.c869
   PubMed Web of Science ®Google Scholar
• Rose M, Bezjak A. Logistics of collecting patient-reported outcomes (PROs) in clinical practice: an overview and practical examples. Qual Life Res. 2009;18(1):125–136. doi:10.1007/s11136-008-9436-0
   PubMed Web of Science ®Google Scholar
• Aaronson N, Choucair A, Elliott T, et al.User’s guide to implementing patient-reported outcomes assessment in clinical practice. Int Soc Qual Life Res. 2015;2:1–47.
   Google Scholar
• Snyder CF, Aaronson NK, Choucair AK, et al. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2012;21(8):1305–1314. doi:10.1007/s11136-011-0054-x
   PubMed Web of Science ®Google Scholar
• Mazariego C, Jefford M, Chan RJ, et al. Priority recommendations for the implementation of patient-reported outcomes in clinical cancer care: a Delphi study. J Cancer Surviv. 2022;16(1):33–43. doi:10.1007/s11764-021-01135-2
   PubMed Web of Science ®Google Scholar
• Snyder C, Brundage M, Rivera YM, et al. A PRO-cision medicine methods toolkit to address the challenges of personalizing cancer care using patient-reported outcomes: introduction to the supplement. Med Care. 2019;57(Suppl5 1):S1–S7. doi:10.1097/MLR.0000000000001089
   PubMedGoogle Scholar